2 Top Growth Stocks to Buy With $1,000 Right Now

The healthcare industry has proved to be a remarkably resilient place for investors. Generally speaking, the kinds of products and services that companies in this space offer are required on a consistent basis. As a result, these businesses are often far less vulnerable to economic fluctuations compared to other industries.

That’s not to say that healthcare businesses haven’t felt the volatility of the last few years, but there’s been a marked difference in the performance of many of these companies that might attract investors looking for steady long-term returns.

If you have $1,000 to invest that you can leave alone for at least several years, here are two such names to consider.

1. Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) is not a household name, but it’s making significant strides in disrupting the standard of care for multiple diseases in substantial addressable markets. For years, it’s been known for its cystic fibrosis medicines that are the only drugs approved to treat the underlying cause of this genetic illness.

Just recently, Vertex added a new product to its portfolio with the approval of the CRISPR-based therapy Casgevy. Vertex developed it in partnership with CRISPR Therapeutics, and it is a potential cure for both sickle cell disease and transfusion-dependent beta thalassemia.

Casgevy has been approved in the U.S., the U.K., Saudi Arabia, and Bahrain, and approval is pending with European Union regulators. Vertex is awaiting approval for Casgevy in Switzerland as well, and there are plans to seek approval for the drug in Canada in the first half of this year.

Looking to Vertex’s very promising pipeline, a number of potential blockbusters bear watching. One is a non-opioid candidate for acute pain called VX-548. The drug has shown significant promise across multiple clinical settings, including surgical and non-surgical pain, giving it disruptive potential in a broad total addressable market.

Story continues

The company is also advancing…